PARIS: Sanofi, a global healthcare company, has sent the first batch of its not-for-profit Impact brand medicines to Djibouti, a country in East Africa. The medicines are part of Sanofi’s Global Health Unit (GHU), which aims to provide access to quality medicines and healthcare for 40 countries with the highest unmet medical needs.
The first medicine to arrive in Djibouti is Enoxaparin Sodium Impact, an anticoagulant medicine used to treat blood clots, a potentially fatal condition that is often underdiagnosed in Africa.
The delivery of the medicine follows a partnership between Sanofi and Djibouti’s national social security fund, which seeks to improve the diagnosis and management of cardiometabolic diseases and diabetes in the country.
Sanofi plans to ship another Impact brand medicine, Insulin Glargine Impact, to Tanzania soon. The Impact brand portfolio consists of 30 medicines that cover various diseases, such as diabetes, cardiovascular disease, tuberculosis, malaria and cancer.
Sanofi’s GHU also works with local communities, authorities and non-governmental organizations to support the development of sustainable healthcare systems, disease awareness programs and training for healthcare professionals.
According to the World Health Organization (WHO), half of the world’s population lacks coverage for essential health services, and noncommunicable diseases are responsible for 41 million deaths each year, mostly in low- and middle-income countries.
Sanofi announces €300 million collaboration with Blackstone Life Sciences
